Proteomics: A new perspective for cancer


1 Department of Oral and Maxillofacial Pathology and Microbiology, Vishnu Dental College, Vishnupur, Bhimavarm, Andhra Pradesh, India

2 Department of Pedodontics, Sri Balaji Dental College and Hospital, Chennai, Tamil Nadu, India

3 Department of Oral and Maxillofacial Pathology and Microbiology, College of Dental Sciences, Davangere, Karnataka, India


In the past decades, several ground breaking discoveries in life science were made. The completion of sequencing the human genome certainly belongs to the key tasks successfully completed, representing a true milestone in the biomedicine. The accomplishment of the complete genome also brings along a new, even more challenging task for scientists: The characterization of the human proteome. Proteomics, the main tool for proteome research, is a relatively new and extremely dynamically evolving branch of science, focused on the evaluation of gene expression at proteome level. Due to the specific properties of proteins, current proteomics deals with different issues, such as protein identification, quantification, characterization of post-translational modification, structure and function elucidation, and description of possible interactions. This field incorporates technologies that can be applied to serum and tissue in order to extract important biological information in the form of biomarkers to aid clinicians and scientists in understanding the dynamic biology of their system of interest, such as a patient with cancer. The present review article provides a detail description of proteomics and its role in cancer research.


Clark DP. Proteomics: The global analysis of proteins. Molecular Biology-Understanding the Genetic Revolution. Ch. 26. London: Elsevier Publication; 2005. p. 718-25.  Back to cited text no. 1
Posadas EM, Simpkins F, Liotta LA, MacDonald C, Kohn EC. Proteomic analysis for the early detection and rational treatment of cancer: Realistic hope? Ann Oncol 2005;16:16-22.  Back to cited text no. 2
Cho WC. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 2007;6:25.  Back to cited text no. 3
Kiernan UA. Biomarker rediscovery in diagnostics. Expert Opin Med Diagn 2008;2:1391-400.  Back to cited text no. 4
Patricelli MP. Activity-based probes for functional proteomics. Brief Funct Genomic Proteomic 2002;1:151-8.  Back to cited text no. 5
Tyers M, Mann M. From genomics to proteomics. Nature 2003;422:193-7.  Back to cited text no. 6
Aebersold R, Cravatt BF. Proteomics: Advances, applications and the challenges that remain. Trends Biotechnol 2002;20:S1-2.  Back to cited text no. 7
Patterson SD, Aebersold RH. Proteomics: The first decade and beyond. Nat Genet 2003;33:311-23.  Back to cited text no. 8
Klein JB, Thongboonkerd V. Overview of proteomics. Contrib Nephrol 2004;141:1-10.  Back to cited text no. 9
Pardanani A, Wieben ED, Spelsberg TC, Tefferi A. Primer on medical genomics. Part IV: Expression proteomics. Mayo Clin Proc 2002;77:1185-96.  Back to cited text no. 10
Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000;405:837-46.  Back to cited text no. 11
Pierce JD, Fakhari M, Works KV, Pierce JT, Clancy RL. Understanding proteomics. Nurs Health Sci 2007;9:54-60.  Back to cited text no. 12
Kenyon GL, DeMarini DM, Fuchs E, Galas DJ, Kirsch JF, Leyh TS, et al. Defining the mandate of proteomics in the post-genomics era: Workshop report. Mol Cell Proteomics 2002;1:763-80.  Back to cited text no. 13
Resing KA, Ahn NG. Proteomics strategies for protein identification. FEBS Lett 2005;579:885-9.  Back to cited text no. 14
Mattow J, Schmidt F, Höhenwarter W, Siejak F, Schaible UE, Kaufmann SH. Protein identification and tracking in two-dimensional electrophoretic gels by minimal protein identifiers. Proteomics 2004;4:2927-41.  Back to cited text no. 15
Gu S, Chen X. Precise proteomic identification using mass spectrometry coupled with stable isotope labeling. Analyst 2005;130:1225-31.  Back to cited text no. 16
McCormack AL. Mass spectrometry in proteomics. Methods 2005;35:209-10.  Back to cited text no. 17
Stults JT, Arnott D. Proteomics. Methods Enzymol 2005;402:245-89.  Back to cited text no. 18
Marik J, Lam KS. Peptide and small-molecule microarrays. Methods Mol Biol 2005;310:217-26.  Back to cited text no. 19
Bertone P, Snyder M. Advances in functional protein microarray technology. FEBS J 2005;272:5400-11.  Back to cited text no. 20
Fung ET, Wright GL Jr, Dalmasso EA. Proteomic strategies for biomarker identification: Progress and challenges. Curr Opin Mol Ther 2000;2:643-50.  Back to cited text no. 21
Hanash S. Disease proteomics. Nature 2003;422:226-32.  Back to cited text no. 22
Tambor V, Fucíková A, Lenco J, Kacerovský M, Rehácek V, Stulík J, et al. Application of proteomics in biomarker discovery: A primer for the clinician. Physiol Res 2010;59:471-97.  Back to cited text no. 23
Zhang DY, Ye F, Gao L, Liu X, Zhao X, Che Y, et al. Proteomics, pathway array and signaling network-based medicine in cancer. Cell Div 2009;4:20.  Back to cited text no. 24
Veenstra TD, Prieto DA, Conrads TP. Proteomic patterns for early cancer detection. Drug Discov Today 2004;9:889-97.  Back to cited text no. 25
Yarbrough WG, Slebos RJ, Liebler D. Proteomics: Clinical applications for head and neck squamous cell carcinoma. Head Neck 2006;28:549-58.  Back to cited text no. 26
Chung CH, Levy S, Chaurand P, Carbone DP. Genomics and proteomics: Emerging technologies in clinical cancer research. Crit Rev Oncol Hematol 2007;61:1-25.  Back to cited text no. 27
Anderson NL, Anderson NG. The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-67.  Back to cited text no. 28
Banks RE, Dunn MJ, Hochstrasser DF, Sanchez JC, Blackstock W, Pappin DJ, et al. Proteomics: New perspectives, new biomedical opportunities. Lancet 2000;356:1749-56.  Back to cited text no. 29